Party members in pharmaceutical factories learn the spirit of the Fifth Plenary Session of the 19th CPC Central Committee
Release time:
2020-12-22
Pharmaceutical Factory Party Members Learn the Spirit of the Fifth Plenary Session of the 19th CPC Central Committee
On the afternoon of November 9, the Party Branch of Jianfeng Pharmaceutical Factory held a special meeting of Party members to organize all Party members to learn the spirit of the Fifth Plenary Session of the 19th CPC Central Committee.
All Party members learned together the explanation of the "Proposal of the CPC Central Committee on Formulating the 14th Five-Year Plan for National Economic and Social Development and the 2035 Long-Term Goals" adopted by the Fifth Plenary Session of the 19th CPC Central Committee, how to achieve the 2035 long-term goals, what are the key goals of economic and social development during the 14th Five-Year Plan period, and why the emphasis is placed on adhering to the overall leadership of the Party and strengthening the centralized and unified leadership of the Party Central Committee, what are the main risks and challenges facing economic development in the next five years, what are the measures to promote consumption, how to narrow the income gap, how to achieve scientific and technological self-reliance and promote innovation, how China will carry out scientific and technological opening and cooperation in the future, what are the arrangements for cultural construction, how to understand the new development pattern of building a double cycle, is there any possibility of decoupling between the Chinese and US economies, and how can China overcome the "middle-income trap", what does the "14th Five-Year Plan" mean to Hong Kong and what opportunities it will bring? The core of the "Proposal" of the "14th Five-Year Plan" and the five principles, two centenary and other hot content. Dai Jinxiao, branch secretary of
Pharmaceutical Factory, asked all party members to earnestly study and implement the spirit of the Fifth Plenary Session of the 19th Central Committee of the Party, firmly establish the "four consciousnesses", strengthen the "four confidences", and resolutely achieve the "two safeguards", and take the initiative to comprehensively Improve one's own consciousness, be brave to take responsibility, use practical actions to safeguard the overall situation of the enterprise, and promote the better and faster development of pharmaceutical factory. At the
meeting, after full discussion and deliberation, all party members also voted to turn probationary party member Yang Xinfeng into a full party member. (Zhang Zhijian)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page